紫丁香苷通过激活SIRT3改善脓毒症小鼠心肌线粒体动力学和减轻氧化应激损伤

doi:10.12122/j.issn.1673-4254.2026.10.21

摘要/Abstract

摘要：

目的探究紫丁香苷（SYR）对脓毒症小鼠心肌的保护作用及其机制。方法使用C57小鼠构建脓毒症模型，分为假手术组、假手术+SYR组、脓毒症（CLP）组、CLP+SYR组、CLP+SYR+3-TYP组（SIRT3抑制剂）。采用超声检测心功能，HE染色评估心肌损伤，ELISA检测血清cTnt、LDH、MDA、SOD、GSH-Px水平；免疫组化和荧光检测活性氧水平以及p-DRP1、MFN1、NOX4表达；Western blotting分析SIRT3/NOX2/p-DRP1等通路蛋白；原代小鼠心肌细胞（MNCMs）使用LPS处理以构建脓毒症模型，分为对照组、LPS组、LPS+SYR组、LPS+SYR+3-TYP组、LPS+Honokiol组。免疫荧光检测线粒体膜电位变化。Western blotting分析SIRT3/NOX2/p-DRP1通路蛋白表达水平。结果与假手术组相比，CLP组心功能下降，心肌组织损伤增加，血清cTnt， LDH含量增加（P<0.01），氧化应激标志蛋白和线粒体损伤蛋白升高（P<0.01）。与CLP组相比，CLP+SYR组心脏组织结构完整，心功能恢复，线粒体损伤减轻，氧化应激减少。与CLP+SYR组相比，CLP+SYR+3-TYP组的MDA和cTnt升高（P<0.01），SOD下降，活性氧水平增加，氧化应激标志蛋白和线粒体损伤蛋白升高（P<0.01）。在NMCMs中，LPS处理导致线粒体膜电位降低，AC-SOD2， NOX2和p-DRP1蛋白升高（P<0.01），MFN1水平下降。LPS+SYR处理可保护细胞免受LPS诱导的氧化应激和线粒体损伤，但这一作用被3-TYP抑制，此外，使用小干扰RNA抑制SIRT3蛋白后，SYR的保护作用消失。结论 SYR通过激活SIRT3的表达，可有效减轻脓毒症诱导的心肌损伤，改善心功能，抑制氧化应激并减轻线粒体损伤。

关键词: 紫丁香苷, 脓毒症, 线粒体, 氧化应激, SIRT3

Abstract:

Objective To investigate the protective effects of syringin against septic myocardial injury and explore the underlying mechanisms. Methods Thirty C57 mice were randomly assigned to receive sham operation with or without subsequent syringin treatment or sepsis modeling by cecal ligation and puncture (CLP) followed by intraperitoneal injection of saline, syringin, or both syringin and 3-TYP (an SIRT3 inhibitor). Cardiac function and myocardial injury of the mice were assessed with echocardiography and HE staining, and serum cTnT, LDH, MDA, SOD, and GSH-Px levels were detected using ELISA. ROS production and expressions of p-DRP1, MFN1, and NOX4 were detected with immunohistochemistry and immunofluorescence staining, and the expressions of the SIRT3/NOX2/p-DRP1 pathway proteins were determined with Western blotting. In primary culture of neonatal mouse cardiomyocytes (NMCMs) treated with lipopolysaccharide (LPS), the effects of syringin, syringin combined with 3-TYP, and honokiol on mitochondrial membrane potential and expression of the SIRT3/NOX2/p-DRP1 pathway were analyzed by immunofluorescence staining and Western blotting. Results CLP mice exhibited significant impairment of cardiac function, obvious myocardial injury, elevated serum cTnT and LDH levels, and increased expression of oxidative stress- and mitochondrial injury-related proteins. Syringin treatment significantly improved myocardial structure and cardiac function, attenuated oxidative stress, and reduced mitochondrial damage in the CLP mice. Treatment with 3-TYP significantly abolished the protective effects of syringin and resulted in increased MDA and cTnT levels, decreased SOD activity, elevated ROS production, and increased expressions of oxidative stress and mitochondrial injury markers. In NMCMs, LPS stimulation obviously reduced mitochondrial membrane potential, increased AC-SOD2, NOX2, and p-DRP1 expressions, and decreased MFN1 levels. Syringin significantly alleviated LPS-induced oxidative stress and mitochondrial dysfunction, and these effects were abolished by 3-TYP treatment or SIRT3 silencing. Conclusion Syringin attenuates sepsis-induced myocardial injury by activating SIRT3 to improve cardiac function, suppress oxidative stress, and alleviate mitochondrial damage.

Key words: syringin, sepsis, mitochondria, oxidative stress, SIRT3

刘燕, 张洪齐. 紫丁香苷通过激活SIRT3改善脓毒症小鼠心肌线粒体动力学和减轻氧化应激损伤[J]. 南方医科大学学报, 2026, 46(10): 2536-2547.

Yan LIU, Hongqi ZHANG. Syringin improves myocardial mitochondrial dynamics and alleviates oxidative stress injury in septic mice by activating SIRT3[J]. Journal of Southern Medical University, 2026, 46(10): 2536-2547.

图/表 8

表1 引物序列

Tab.1 Primer sequences for RT-qPCR

Gene	Forward primer	Reverse primer
NOX2	TGCCAACTTCCTCAGCTACAATA	GTGTTCACTTGCAATGGTCTTGA
NRF2	TGGCAGAGACATTCCCATTTGTA	CTTGCTCCATGTCCTGCTCTATG
NOX4	CCTCCTGGCTGCATTAGTCTTAA	AAAGGCACAAAGGTCCAGAAATC
GAPDH	GGCATTGTGGAAGGGCTCAT	AGATCCACGACGGACACATT

图1 SYR减轻脓毒症小鼠心肌损伤

Fig.1 Syringin (SYR) alleviates myocardial injury in mice with sepsis. A: Representative left ventricular M-mode echocardiograms of the mice in different groups. B: Statistical analysis of heart rate (n=6). C: Statistical analysis of LVEF (n=6). D: Statistical analysis of LVFS (n=6). E: Serum cTnt levels in the mice. F: LDH activity in mouse serum. G: Survival rates of the mice with or without SYR therapy 24 h after cecal ligation and puncture (CLP) (n=20). Time (h) refers to the survival hours after sepsis. H: HE staining (Scale bar=100 μm). *P<0.05, **P<0.01, ****P<0.0001.

图2 SYR治疗减轻脓毒症小鼠氧化应激相关基因和蛋白表达

Fig.2 SYR treatment alleviates sepsis-induced aberrant expressions of oxidative stress-related genes and proteins in mice. A: NOX2, NRF2 and NOX4 mRNA levels in mouse myocardial tissue. B: Target proteins examined by Western blotting. C: Statistical analysis of NRF2/GAPDH (n=6). D: Statistical analysis of SIRT3/GAPDH (n=6). E: Statistical analysis of SOD2/GAPDH (n=6). F: Statistical analysis of AC-SOD2/GAPDH (n=6). G: Statistical analysis of NQO1/GAPDH (n=6). H: Statistical analysis of NOX2/GAPDH (n=6). Comparisons among multiple groups were made using one-way ANOVA. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图3 SYR治疗减轻脓毒症小鼠血清和组织氧化应激水平

Fig.3 SYR treatment reduces the levels of oxidative stress in the serum and tissues of septic mice. A: MDA content in mouse serum (n=6). B: GSH-Px content in mouse serum (n=6). C: SOD content in mouse serum (n=6). D: Expression and location of NOX4 determined by immunohistochemistry (Scale bar=100 μm). E: Statistical analysis of NOX4 area (n=6). F: Expression and location of 8-OHdG determined by immunofluorescence staining (Scale bar=100 μm). G: Statistical analysis of fluorescence intensity (n=6). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图4 SYR治疗减轻脓毒症小鼠线粒体损伤

Fig.4 SYR treatment alleviates mitochondrial damage in septic mice. A: Expression and location of MFN1 determined by immunofluorescence staining (Scale bar=100 μm). B: Statistical analysis of fluorescence intensity (n=6). C: Expression and location of p-DRP1 were determined by immunohistochemistry (Scale bar=100 μm). D: Statistical analysis of p-DRP1 area (n=6). E: Target proteins examined by Western blotting. F: Statistical analysis of p-DRP1(S616)/DRP1 (n=6). G: Statistical analysis of MFN1/GAPDH (n=6). *P<0.05, ***P<0.001, ****P<0.0001.

图5 SYR通过激活SIRT3减轻新生小鼠心肌细胞氧化应激和线粒体损伤

Fig.5 SYR attenuates oxidative stress and mitochondrial damage in primary culture of neonatal mouse cardiomyocytes (NMCMs) by activating SIRT3. A: Expression of DCFH-DA determined by immunofluorescence staining (Scale bar=200 μm). B: Statistical analysis of fluorescence intensity (n=6). C: JC-1 staining for measuring the mitochondrial membrane potential in NMCMs showing depolarization (green) and hyperpolarization (red) of the mitochondria. D: Statistical analysis of fluorescence intensity (n=6). E: Target proteins examined by Western blotting. F: Statistical analysis of SIRT3/GAPDH (n=6). G: Statistical analysis of p-DRP1/DRP1 (n=6). H: Statistical analysis of MFN1/GAPDH (n=6). I: Statistical analysis of AC-SOD2/GAPDH (n=6). J: Statistical analysis of NOX2/GAPDH (n=6). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

图6 抑制SIRT3可消除SYR对新生小鼠心肌细胞氧化应激抑制和线粒体的保护作用

Fig.6 Inhibiting SIRT3 eliminates the inhibitory effects of SYR on oxidative stress in neonatal mouse cardiomyocytes and its protective effect on mitochondria. A: Expression of DCFH-DA determined by immunofluorescence staining (Scale bar=200 μm). B: Statistical analysis of fluorescence intensity (n=6). C: Target proteins examined by Western blotting. D: Statistical analysis of SIRT3/GAPDH (n=6). E: Statistical analysis of p-DRP1/DRP1 (n=6). F: Statistical analysis of MFN1/GAPDH (n=6). G: Statistical analysis of AC-SOD2/GAPDH (n=6). H: Statistical analysis of NOX2/GAPDH (n=6). ***P<0.001, ****P<0.0001.

图7 SYR通过激活SIRT3从而在脓毒症小鼠心肌中发挥保护作用

Fig.7 SYR produces protective effect on the myocardium in septic mice by activating SIRT3. A: Representative electron microscopy images showing damaged mitochondrial with loss of cristae in mouse cardiomyocytes (Scale bar=500 nm). B: Quantification of damaged mitochondria in mouse cardiomyocytes (n=6). C: MDA content in mouse serum (n=6). D: cTnt content in mouse (n=6). E: SOD content in mouse serum (n=6). F: Target proteins examined by Western blotting. G: Statistical analysis of SIRT3/GAPDH (n=6). H: Statistical analysis of SOD2/GAPDH (n=6). I: Statistical analysis of p-DRP1/DRP1 (n=6). J: Statistical analysis of NOX2/GAPDH (n=6). K: Statistical analysis of NQO1/GAPDH (n=6). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

参考文献 32

[1]	Sato R, Sanfilippo F, Lanspa M, et al. Sepsis-induced cardio-myopathy[J]. Chest, 2025, 168(6): 1383-94. doi：10.1016/j.chest.2025.08.013
[2]	Pamporis K, Karakasis P, Pantelidaki A, et al. Sepsis-induced cardiomyopathy and cardiac arrhythmias: pathophysiology and implications for novel therapeutic approaches[J]. Biomedicines, 2025, 13(11): 2643. doi：10.3390/biomedicines13112643
[3]	Hasegawa D, Ishisaka Y, Maeda T, et al. Prevalence and prognosis of sepsis-induced cardiomyopathy: a systematic review and meta-analysis[J]. J Intensive Care Med, 2023, 38(9): 797-808. doi：10.1177/08850666231180526
[4]	Shvilkina T, Shapiro N. Sepsis-Induced myocardial dysfunction: heterogeneity of functional effects and clinical significance[J]. Front Cardiovasc Med, 2023, 10: 1200441. doi：10.3389/fcvm.2023.1200441
[5]	L' Heureux M, Sternberg M, Brath L, et al. Sepsis-induced cardiomyopathy: a comprehensive review[J]. Curr Cardiol Rep, 2020, 22(5): 35. doi：10.1007/s11886-020-01277-2
[6]	Marques E, Kramer R, Ryan DG. Multifaceted mitochondria in innate immunity[J]. npj Metab Health Dis, 2024, 2: 6. doi：10.1038/s44324-024-00008-3
[7]	Kuroshima T, Kawaguchi S, Okada M. Current perspectives of mitochondria in sepsis-induced cardiomyopathy[J]. Int J Mol Sci, 2024, 25(9): 4710. doi：10.3390/ijms25094710
[8]	Nedel W, Strogulski NR, Kopczynski A, et al. Assessment of mitochondrial function and its prognostic role in sepsis: a literature review[J]. Intensive Care Med Exp, 2024, 12(1): 107. doi：10.1186/s40635-024-00694-9
[9]	Chen W, Zhao ZZ, Geng ZG, et al. Advances in mitochondria-nucleus crosstalk in septic cardiomyopathy[J]. Cell Biol Toxicol, 2025, 41(1): 136. doi：10.1007/s10565-025-10090-y
[10]	West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology[J]. Nat Rev Immunol, 2017, 17(6): 363-75. doi：10.1038/nri.2017.21
[11]	Yao X, Carlson D, Sun YX, et al. Mitochondrial ROS induces cardiac inflammation via a pathway through mtDNA damage in a pneumonia-related sepsis model[J]. PLoS One, 2015, 10(10): e0139416. doi：10.1371/journal.pone.0139416
[12]	Hu DX, Sheeja Prabhakaran H, Zhang YY, et al. Mitochondrial dysfunction in sepsis: mechanisms and therapeutic perspectives[J]. Crit Care, 2024, 28(1): 292. doi：10.1186/s13054-024-05069-w
[13]	董永杰, 董静, 岳峰, 等. 紫丁香苷调节PD-1/PD-L1信号通路对胃癌细胞增殖、凋亡和免疫逃逸的影响 [J]. 中国老年学杂志, 2025, 45(17): 4304-8.
[14]	任兰鑫, 左振魁, 王琳, 等. 基于JAK2/STAT3信号通路探究紫丁香苷对溃疡性结肠炎肠上皮细胞凋亡的影响 [J]. 中药材, 2025, 48(6): 1528-33.
[15]	Niu HS, Liu IM, Cheng JT, et al. Hypoglycemic effect of syringin from Eleutherococcus senticosus in streptozotocin-induced diabetic rats[J]. Planta Med, 2008, 74(2): 109-13. doi：10.1055/s-2008-1034275
[16]	Zhao D, Liu KT, Wang J, et al. Syringin exerts anti-inflammatory and antioxidant effects by regulating SIRT1 signaling in rat and cell models of acute myocardial infarction[J]. Immunity Inflam & Disease, 2023, 11(2): e775. doi：10.1002/iid3.775
[17]	Yao JP, Li Y, Jin YP, et al. Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF‑κB/NLRP3 and PGC1a/SIRT3 pathways[J]. Int Immunopharmacol, 2021, 96: 107728. doi：10.1016/j.intimp.2021.107728
[18]	Xu ZW, Huang FJ, Wu ZM, et al. Syringin attenuates Alzheimer's disease-associated neuroinflammation by inhibiting NLRP3 inflammasome activation[J]. Phytomedicine, 2025, 148: 157454. doi：10.1016/j.phymed.2025.157454
[19]	Wang WL, Feng XY, Guo X, et al. Syringin attenuates fibrogenesis and inflammation through SIRT3-regulated P2X7 receptor signaling pathway in hepatic fibrosis[J]. Phytomedicine, 2025, 148: 157461. doi：10.1016/j.phymed.2025.157461
[20]	Peng YC, Xu J, Wei LY, et al. Melatonin alleviates sepsis-induced acute lung injury by inhibiting necroptosis via reducing circulating mtDNA release[J]. Mol Med, 2025, 31(1): 176. doi：10.1186/s10020-025-01228-z
[21]	Guo ML, Zhuang HJ, Su YM, et al. SIRT3 alleviates imiquimod-induced psoriatic dermatitis through deacetylation of XBP1s and modulation of TLR7/8 inducing IL-23 production in macrophages[J]. Front Immunol, 2023, 14: 1128543. doi：10.3389/fimmu.2023.1128543
[22]	彭煜策, 姜毅, 马丹, 等. 异牡荆素通过促进SIRT3表达减轻糖尿病小鼠的心肌氧化应激损伤 [J]. 南方医科大学学报,2026,46(2): 316-24.
[23]	Marconi GD, Della Rocca Y, Fonticoli L, et al. The beneficial effect of carvacrol in HL-1 cardiomyocytes treated with LPS-G: anti-inflammatory pathway investigations[J]. Antioxidants, 2022, 11(2): 386. doi：10.3390/antiox11020386
[24]	Huang pian-pian, Fu J, Liu li-hua, et al. Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation[J]. Int J Mol Med, 2019,45(1): 186-94.
[25]	Yu WL, Lyu JS, Jia LL, et al. Dexmedetomidine ameliorates hippocampus injury and cognitive dysfunction induced by hepatic ischemia/reperfusion by activating SIRT3-mediated mitophagy and inhibiting activation of the NLRP3 inflammasome in young rats[J]. Oxid Med Cell Longev, 2020, 2020: 7385458. doi：10.1155/2020/7385458
[26]	Aissaoui N, Boissier F, Chew M, et al. Sepsis-induced cardiomyopathy[J]. Eur Heart J, 2025, 46(34): 3339-53. doi：10.1093/eurheartj/ehaf340
[27]	Yu XT, Gao J, Zhang CX. Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism[J]. Intensive Care Med Exp, 2025, 13(1): 20. doi：10.1186/s40635-025-00728-w
[28]	Haileselassie B, Mukherjee R, Joshi AU, et al. Drp1/Fis1 interaction mediates mitochondrial dysfunction in septic cardiomyopathy[J]. J Mol Cell Cardiol, 2019, 130: 160-9. doi：10.1016/j.yjmcc.2019.04.006
[29]	Liu AB, Wang S, Shen Y, et al. The role of mitochondrial dysfunction and inflammatory response in the pathogenesis of sepsis-induced myocardial injury: a mechanistic study[J]. J Inflamm Res, 2025, 18: 15207-35. doi：10.2147/jir.s552730
[30]	Bertozzi G, Ferrara M, Di Fazio A, et al. Oxidative stress in sepsis: a focus on cardiac pathology[J]. Int J Mol Sci, 2024, 25(5): 2912. doi：10.3390/ijms25052912
[31]	Wan CL, Sun SY, Du YQ, et al. A study on the mechanism of action of Syringin in the treatment of type 2 diabetes by integrating metabolomics, network pharmacology, molecular docking technology and experimental validation[J]. Int Immunopharmacol, 2025, 167: 115716. doi：10.1016/j.intimp.2025.115716
[32]	Cai XM, Wu YN, Liu FX, et al. Syringin alleviates ROS-induced acute lung injury by activating SIRT1/STAT6 signaling pathway to inhibit ferroptosis[J]. Tissue Cell, 2025, 93: 102698. doi：10.1016/j.tice.2024.102698